Strides Pharma Science Limited Announces Final Dividend Recommendation and Sets Record Date for AGM
Strides Pharma Science Limited has announced key dates regarding its upcoming Annual General Meeting (AGM) and the recommendation of a final dividend for the financial year ended March 31, 2026. The company set July 31, 2026, as the record date to determine shareholder entitlement for the proposed payment.The Board of Directors of Strides Pharma Science Limited, during a meeting held on May 18, 2026, recommended a Final Dividend of ₹5 per equity share. This dividend represents 50% of the face value and is based on the company's financial performance for the fiscal year ending March 31, 2026.
The Annual General Meeting (AGM) has been scheduled for Friday, August 14, 2026, at 12:15 hrs IST, which will be conducted through Video Conferencing (VC) and Other Audio-Visual Means (OAVM).
To ensure all relevant shareholders are entitled to receive the dividend should it be approved at the AGM, the company fixed July 31, 2026, as the Record Date. The recommended Final Dividend is subject to shareholder approval at the ensuing AGM.
The company also provided details regarding the payout process. If the final dividend receives shareholder approval, payment will be made within 30 days from its declaration date. Payments will utilize permissible electronic modes to shareholders whose bank account details are registered with the Depositories and/or the Company's Registrar and Share Transfer Agent (RTA), subject to applicable tax deductions at source.
STAR Stock Price Movement
As of 1:10 PM, shares of Strides Pharma Science Limited are slipping by 0.39% in live trading, currently at ₹1070.7 after shedding ₹4.20 from its previous close. The stock traded a volume of 59,889 shares during the session, reflecting ongoing activity in the market.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.